{"id":2372,"date":"2025-05-22T15:28:57","date_gmt":"2025-05-22T13:28:57","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2372"},"modified":"2025-12-11T15:38:40","modified_gmt":"2025-12-11T14:38:40","slug":"a-covid-19-oltoanyag-eredmenyessege-europaban-a-tunetes-sars-cov-2-fertozessel-szemben-a-celcsoportok-koreben-2024-oktober-2025-januar-vebis-haziorvosi-halozat","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2025\/05\/22\/a-covid-19-oltoanyag-eredmenyessege-europaban-a-tunetes-sars-cov-2-fertozessel-szemben-a-celcsoportok-koreben-2024-oktober-2025-januar-vebis-haziorvosi-halozat\/","title":{"rendered":"A Covid-19 olt\u00f3anyag eredm\u00e9nyess\u00e9ge Eur\u00f3p\u00e1ban a t\u00fcnetes SARS-CoV-2-fert\u0151z\u00e9ssel szemben a c\u00e9lcsoportok k\u00f6r\u00e9ben, 2024. okt\u00f3ber\u20132025. janu\u00e1r, VEBIS* h\u00e1ziorvosi h\u00e1l\u00f3zat"},"content":{"rendered":"

A 2024\/25 \u00e9vi szezonban a Covid\u201319 JN.1 \u00e9s KP.2 vari\u00e1nsai elleni olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t (VE) vizsg\u00e1ltuk azokban az olt\u00e1si kamp\u00e1nyok szerint meghat\u00e1rozott c\u00e9lcsoportokban, akik t\u00fcnetes SARS-CoV-2 fert\u0151z\u00e9ssel kerest\u00e9k fel h\u00e1ziorvosukat \u00e9s megfeleltek az ARI** esetdefin\u00edci\u00f3nak. A kutat\u00e1s Eur\u00f3pa t\u00f6bb orsz\u00e1g\u00e1ban zajlott, egy t\u00f6bbk\u00f6zpont\u00fa vizsg\u00e1lat keret\u00e9ben val\u00f3sult meg az alapell\u00e1t\u00e1sban, az elemz\u00e9st teszt-negat\u00edv<\/em> m\u00f3dszertannal v\u00e9gezt\u00fck.<\/p>\n

A vizsg\u00e1latban a SARS-CoV-2 pozit\u00edv RT-PCR teszteredm\u00e9nnyel rendelkez\u0151 betegek ker\u00fcltek az esetek csoportj\u00e1ba, m\u00edg a kontrollcsoportba azok tartoztak, akiknek a tesztje negat\u00edv eredm\u00e9nyt mutatott. 2024. okt\u00f3ber \u00e9s 2025. janu\u00e1r k\u00f6z\u00f6tt \u00f6sszesen 3\u00a0204 r\u00e9sztvev\u0151t toboroztunk a vizsg\u00e1latba. M\u00edg l\u00e9g\u00fati szezonban az esetek 6%-a r\u00e9szes\u00fclt a COVID-19 elleni v\u00e9d\u0151olt\u00e1sban, addig a kontrollok 17%-a kapott olt\u00e1st.<\/p>\n

Az Covid-19 elleni olt\u00f3anyagok eredm\u00e9nyess\u00e9g\u00e9t a teljes popul\u00e1ci\u00f3ban 66%-nak m\u00e9rt\u00fck. Az olt\u00e1st k\u00f6vet\u0151 els\u0151 h\u00f3napban m\u00e9rt VE magasabb, mintegy 73%, a m\u00e1sodik h\u00f3napban pedig 54% volt. Az id\u0151sebb feln\u0151ttek (\u226560 vagy \u226565 \u00e9vesek) k\u00f6r\u00e9ben a teljes v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g 67% volt. (1. t\u00e1bl\u00e1zat)<\/p>\n

Eredm\u00e9nyeink a kor\u00e1bbi szezonokhoz k\u00e9pest n\u00e9mileg magasabb v\u00e9detts\u00e9get mutatnak a Covid-19 megbeteged\u00e9sekkel szemben. Ugyanakkor az olt\u00e1s \u00f3ta eltelt id\u0151 f\u00fcggv\u00e9ny\u00e9ben megfigyelt v\u00e1ltoz\u00e1sok pontosabb meg\u00e9rt\u00e9hez tov\u00e1bbi, t\u00f6bb r\u00e9sztvev\u0151 bevon\u00e1s\u00e1val v\u00e9gzett vizsg\u00e1latokra van sz\u00fcks\u00e9g.<\/p>\n

    \n
  1. t\u00e1bl\u00e1zat: A t\u00fcnetekkel j\u00e1r\u00f3, PCR-rel igazolt SARS-CoV-2 fert\u0151z\u00e9s elleni \u00f6sszes\u00edtett v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g az olt\u00e1si c\u00e9lcsoportok k\u00f6r\u00e9ben, a VEBIS h\u00e1ziorvosi vizsg\u00e1lat alapj\u00e1n, Eur\u00f3pa, 2024. okt\u00f3ber \u2013 2025. janu\u00e1r<\/strong><\/span><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    R\u00f6vid\u00edt\u00e9sek: VEBIS: Effectiveness, Burden and Impact Studies, TSV: Olt\u00e1s \u00f3ta eltelt id\u0151 (time since vaccination), VE: V\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g, IQR: Interkvartilis tartom\u00e1ny
    \n<\/span>Forr\u00e1s: Influenza Other Respir Viruses. 2025 May 21;19(5):e70120. doi: 10.1111\/irv.70120 publik\u00e1ci\u00f3 alapj\u00e1n 1. t\u00e1bl\u00e1zata alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

     <\/p>\n

    COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network<\/span><\/h3>\n

    Charlotte Laniece Delaunay <\/em>(Epidemiology Department, Epiconcept, Paris, France)
    \nNuno Verdasca<\/em> (Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal)
    \nT\u00fari Gerg\u0151 <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary)
    \nand the European primary care VE group<\/p>\n

    Abstract<\/strong><\/h5>\n

    We estimated the effectiveness of 2024\/25 COVID\u201019 vaccination against medically attended SARS\u2010CoV\u20102 infection in Europe, among target groups. We included 3204 patients (8\/139 cases vaccinated: 6%; 517\/3065 controls vaccinated: 17%) from a multicentre, test\u2010negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34\u201385) overall, 73% (95% CI: 21\u201394) and 54% (95% CI: \u22123 to 83) in the first and second months post\u2010vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33\u201386) among older adults (\u2265\u200960 or \u2265\u200965\u2009years). This relatively high COVID\u201019 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.<\/p>\n

    \u00a0<\/p>\n

    * VEBIS: Effectiveness, Burden and Impact Studies<\/span><\/p>\n

    ** Akut l\u00e9g\u00fati megbeteged\u00e9s (ARI): A t\u00fcnetek hirtelen kezd\u0151dnek \u00e9s az al\u00e1bbi n\u00e9gy\u00a0l\u00e9g\u00fati t\u00fcnet\u00a0k\u00f6z\u00fcl legal\u00e1bb egy fenn\u00e1ll: k\u00f6h\u00f6g\u00e9s, torokf\u00e1j\u00e1s, l\u00e9gszomj, n\u00e1tha, tov\u00e1bb\u00e1 az orvos meg\u00edt\u00e9l\u00e9se szerint a t\u00fcnetek oka fert\u0151z\u00e9s.<\/span><\/p>\n

    Laniece Delaunay C, Verdasca N, Monge S, Domegan L, S\u00e8ve N, Buda S, Meijer A, Lucaccioni H, L\u00f3pez Torrijos M, McKenna A, Enouf V, D\u00fcrrwald R, In’t Velt E, de Valc\u00e1rcel Laiglesia M\u00c1, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinari\u0107 I, T\u00fari G, Rodrigues AP, Mart\u00ednez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111\/irv.70120. PMID: 40395132; PMCID: PMC12093050.<\/span><\/p>\n

    https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.70120<\/strong><\/a><\/p>\n

     <\/p>\n

    K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

    \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

    \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    A 2024\/25 \u00e9vi szezonban a Covid\u201319 JN.1 \u00e9s KP.2 vari\u00e1nsai elleni olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t (VE) vizsg\u00e1ltuk azokban az olt\u00e1si kamp\u00e1nyok szerint meghat\u00e1rozott c\u00e9lcsoportokban, akik t\u00fcnetes SARS-CoV-2 fert\u0151z\u00e9ssel kerest\u00e9k fel h\u00e1ziorvosukat \u00e9s megfeleltek az ARI** esetdefin\u00edci\u00f3nak. A kutat\u00e1s Eur\u00f3pa t\u00f6bb orsz\u00e1g\u00e1ban zajlott, egy t\u00f6bbk\u00f6zpont\u00fa vizsg\u00e1lat keret\u00e9ben val\u00f3sult meg az alapell\u00e1t\u00e1sban, az elemz\u00e9st teszt-negat\u00edv m\u00f3dszertannal v\u00e9gezt\u00fck. A vizsg\u00e1latban …<\/p>\n","protected":false},"author":102284,"featured_media":2373,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2372","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2372"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2372\/revisions"}],"predecessor-version":[{"id":2374,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2372\/revisions\/2374"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2373"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}